{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-301136","form_type":"8-K","ticker":"EW","cik":"0001099800","company_name":"Edwards Lifesciences Corp","filed_at":"2022-12-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.603699+00:00","generated_at":"2026-06-21T07:16:14.233042+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Edwards Lifesciences CEO Mike Mussallem retiring May 2023; Bernard Zovighian to become CEO","bullets":["CEO Mussallem (70) to retire at May 11, 2023 annual meeting; will become non-executive chairman.","Bernard Zovighian named President effective Jan 1, 2023, then CEO on May 11, 2023.","Larry Wood expands to corporate VP and group president for TAVR and Surgical Structural Heart.","Daveen Chopra to succeed Zovighian as head of Transcatheter Mitral & Tricuspid Therapies (TMTT).","Zovighian base salary increased to $800k, incentive target $800k; Wood to $750k each."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-301136","json":"https://secwatch.observer/filing/0001193125-22-301136.json","markdown":"https://secwatch.observer/filing/0001193125-22-301136.md","text":"https://secwatch.observer/filing/0001193125-22-301136.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/d423822d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T07:16:14.233042+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"128dc37e03","claim":"Larry Wood was appointed as Corporate Vice President and Group President at Edwards Lifesciences Corp.","evidence_excerpt":"the Board’s appointment of Larry Wood to an expanded role as corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical Structural Heart effective January 1, 2023","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed to expanded role"},{"label":"Role","value":"Corporate Vice President and Group President"}],"fact_type":"executive_change"},{"claim_id":"46bfedb339","claim":"Bernard J. Zovighian was appointed as Chief Executive Officer at Edwards Lifesciences Corp.","evidence_excerpt":"At the 2023 Annual Meeting, Mr. Mussallem will be succeeded as CEO by Bernard J. Zovighian, currently corporate vice president and general manager for Edwards’ Transcatheter Mitral and Tricuspid Therapies (“TMTT”) business.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"6d9f6fe64e","claim":"Bernard J. Zovighian was appointed as President at Edwards Lifesciences Corp.","evidence_excerpt":"On December 6, 2022 the Board appointed Bernard J. Zovighian as President of the Company, effective January 1, 2023, until he becomes CEO on May 11, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"9ce8d9bc74","claim":"Michael A. Mussallem retired as Non-executive Chairman at Edwards Lifesciences Corp.","evidence_excerpt":"On December 6, 2022, Michael A. Mussallem informed the Board of Directors (the “Board”) of Edwards Lifesciences Corporation, a Delaware corporation (“Edwards” or the “Company”), of his decision to retire as Chief Executive Officer of Edwards in connection with Edwards’ Annual Meeting of Stockholders on May 11, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1099800/000119312522301136/0001193125-22-301136-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Non-executive Chairman"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}